Phase I Clinical Study of E7389
NCT00326950
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
E7389
Sponsor
Eisai Co., Ltd.